In the BioHarmony Drug Report Database

"Preview" Icon

Liraglutide

Saxenda, Victoza (liraglutide) is a protein pharmaceutical. Liraglutide was first approved as Saxenda on 2009-06-30. It has been approved in Europe to treat obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Victoza’s patents are valid until 2037-01-09 (FDA).

 

Trade Name

 

Saxenda, Victoza
 

Common Name

 

liraglutide
 

ChEMBL ID

 

CHEMBL4524066
 

Indication

 

obesity, overweight, type 2 diabetes mellitus
 

Drug Class

 

Peptides: GLP peptide analogs

Image (chem structure or protein)

Liraglutide structure rendering